# Datadog, Inc.: financial statements, quarterly

DDOG · Nasdaq · CIK 1561550 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ddog.md) · [Financials](/companies/ddog/financials.md) · [Filings](/companies/ddog/filings.md) · [Insiders](/companies/ddog/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ddog/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [548](/filings/0001561550-24-000175.md) | [590 d](/filings/0001628280-26-008819.md) | [611](/filings/0001561550-25-000123.md) | [645](/filings/0001561550-25-000220.md) | [690](/filings/0001561550-25-000313.md) | [738 d](/filings/0001628280-26-008819.md) | [762](/filings/0001628280-26-032328.md) | [827](/filings/0001628280-26-054458.md) | [886](/filings/0001561550-25-000313.md) | [953 d](/filings/0001628280-26-008819.md) | [1,006](/filings/0001628280-26-032328.md) | [1,121](/filings/0001628280-26-054458.md) |
| Cost of revenue | $m | [103](/filings/0001561550-24-000175.md) | [105 d](/filings/0001628280-26-008819.md) | [110](/filings/0001561550-25-000123.md) | [123](/filings/0001561550-25-000220.md) | [138](/filings/0001561550-25-000313.md) | [144 d](/filings/0001628280-26-008819.md) | [158](/filings/0001628280-26-032328.md) | [166](/filings/0001628280-26-054458.md) | [176](/filings/0001561550-25-000313.md) | [187 d](/filings/0001628280-26-008819.md) | [209](/filings/0001628280-26-032328.md) | [240](/filings/0001628280-26-054458.md) |
| Gross profit | $m | [444](/filings/0001561550-24-000175.md) | [485 d](/filings/0001628280-26-008819.md) | [501](/filings/0001561550-25-000123.md) | [522](/filings/0001561550-25-000220.md) | [552](/filings/0001561550-25-000313.md) | [594 d](/filings/0001628280-26-008819.md) | [604](/filings/0001628280-26-032328.md) | [661](/filings/0001628280-26-054458.md) | [709](/filings/0001561550-25-000313.md) | [766 d](/filings/0001628280-26-008819.md) | [797](/filings/0001628280-26-032328.md) | [881](/filings/0001628280-26-054458.md) |
| Research and development | $m | [240](/filings/0001561550-24-000175.md) | [253 d](/filings/0001628280-26-008819.md) | [270](/filings/0001561550-25-000123.md) | [275](/filings/0001561550-25-000220.md) | [292](/filings/0001561550-25-000313.md) | [316 d](/filings/0001628280-26-008819.md) | [341](/filings/0001628280-26-032328.md) | [387](/filings/0001628280-26-054458.md) | [402](/filings/0001561550-25-000313.md) | [418 d](/filings/0001628280-26-008819.md) | [435](/filings/0001628280-26-032328.md) | [478](/filings/0001628280-26-054458.md) |
| Operating income | $m | [(4.2)](/filings/0001561550-24-000175.md) | [27.7 d](/filings/0001628280-26-008819.md) | [12.0](/filings/0001561550-25-000123.md) | [12.6](/filings/0001561550-25-000220.md) | [20.3](/filings/0001561550-25-000313.md) | [9.4 d](/filings/0001628280-26-008819.md) | [(12.4)](/filings/0001628280-26-032328.md) | [(35.5)](/filings/0001628280-26-054458.md) | [(5.8)](/filings/0001561550-25-000313.md) | [9.4 d](/filings/0001628280-26-008819.md) | [7.3](/filings/0001628280-26-032328.md) | [5.5](/filings/0001628280-26-054458.md) |
| Interest expense | $m | [1.3](/filings/0001561550-23-000055.md) | [1.3 d](/filings/0001561550-24-000009.md) | [1.4](/filings/0001561550-24-000051.md) | [1.5](/filings/0001561550-25-000220.md) | [1.6](/filings/0001561550-25-000313.md) | [2.6 d](/filings/0001628280-26-008819.md) | [3.0](/filings/0001628280-26-032328.md) | [3.1](/filings/0001628280-26-054458.md) | [2.4](/filings/0001561550-25-000313.md) | [2.6 d](/filings/0001628280-26-008819.md) | [3.1](/filings/0001628280-26-032328.md) | [3.3](/filings/0001628280-26-054458.md) |
| Income tax | $m | [1.7](/filings/0001561550-24-000175.md) | [3.3 d](/filings/0001628280-26-008819.md) | [3.6](/filings/0001561550-25-000123.md) | [4.0](/filings/0001561550-25-000220.md) | [4.4](/filings/0001561550-25-000313.md) | [8.2 d](/filings/0001628280-26-008819.md) | [7.2](/filings/0001628280-26-032328.md) | [3.4](/filings/0001628280-26-054458.md) | [1.8](/filings/0001561550-25-000313.md) | [6.9 d](/filings/0001628280-26-008819.md) | [6.4](/filings/0001628280-26-032328.md) | [7.2](/filings/0001628280-26-054458.md) |
| Net income | $m | [22.6](/filings/0001561550-24-000175.md) | [54.0 d](/filings/0001628280-26-008819.md) | [42.6](/filings/0001561550-25-000123.md) | [43.8](/filings/0001561550-25-000220.md) | [51.7](/filings/0001561550-25-000313.md) | [45.6 d](/filings/0001628280-26-008819.md) | [24.6](/filings/0001628280-26-032328.md) | [2.6](/filings/0001628280-26-054458.md) | [33.9](/filings/0001561550-25-000313.md) | [46.6 d](/filings/0001628280-26-008819.md) | [52.6](/filings/0001628280-26-032328.md) | [44.6](/filings/0001628280-26-054458.md) |
| Diluted EPS | $ per share | [0.06](/filings/0001561550-24-000175.md) | not reported | [0.12](/filings/0001561550-25-000123.md) | [0.12](/filings/0001561550-25-000220.md) | [0.14](/filings/0001561550-25-000313.md) | not reported | [0.07](/filings/0001628280-26-032328.md) | [0.01](/filings/0001628280-26-054458.md) | [0.10](/filings/0001561550-25-000313.md) | not reported | [0.15](/filings/0001628280-26-032328.md) | [0.12](/filings/0001628280-26-054458.md) |
| Basic EPS | $ per share | [0.07](/filings/0001561550-24-000175.md) | not reported | [0.13](/filings/0001561550-25-000123.md) | [0.13](/filings/0001561550-25-000220.md) | [0.15](/filings/0001561550-25-000313.md) | not reported | [0.07](/filings/0001628280-26-032328.md) | [0.01](/filings/0001628280-26-054458.md) | [0.10](/filings/0001561550-25-000313.md) | not reported | [0.15](/filings/0001628280-26-032328.md) | [0.13](/filings/0001628280-26-054458.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [261](/filings/0001561550-24-000175.md) | [330](/filings/0001561550-25-000025.md) | [282](/filings/0001561550-24-000051.md) | [411](/filings/0001561550-24-000112.md) | [337](/filings/0001561550-24-000175.md) | [1,247](/filings/0001628280-26-008819.md) | [1,080](/filings/0001561550-25-000123.md) | [489](/filings/0001561550-25-000220.md) | [541](/filings/0001561550-25-000313.md) | [401](/filings/0001628280-26-054458.md) | [426](/filings/0001628280-26-032328.md) | [435](/filings/0001628280-26-054458.md) |
| Current assets | $m | [2,819](/filings/0001561550-23-000055.md) | [3,178](/filings/0001561550-25-000025.md) | [3,334](/filings/0001561550-24-000051.md) | [3,592](/filings/0001561550-24-000112.md) | [3,789](/filings/0001561550-24-000175.md) | [4,911](/filings/0001628280-26-008819.md) | [5,076](/filings/0001561550-25-000123.md) | [4,645](/filings/0001561550-25-000220.md) | [4,838](/filings/0001561550-25-000313.md) | [5,382](/filings/0001628280-26-054458.md) | [5,625](/filings/0001628280-26-032328.md) | [6,009](/filings/0001628280-26-054458.md) |
| Total assets | $m | [3,543](/filings/0001561550-23-000055.md) | [3,936](/filings/0001561550-25-000025.md) | [4,141](/filings/0001561550-24-000051.md) | [4,412](/filings/0001561550-24-000112.md) | [4,631](/filings/0001561550-24-000175.md) | [5,785](/filings/0001628280-26-008819.md) | [6,010](/filings/0001561550-25-000123.md) | [5,822](/filings/0001561550-25-000220.md) | [6,052](/filings/0001561550-25-000313.md) | [6,644](/filings/0001628280-26-054458.md) | [6,952](/filings/0001628280-26-032328.md) | [7,548](/filings/0001628280-26-054458.md) |
| Current liabilities | $m | [842](/filings/0001561550-23-000055.md) | [1,003](/filings/0001561550-25-000025.md) | [973](/filings/0001561550-24-000051.md) | [1,791](/filings/0001561550-24-000112.md) | [1,780](/filings/0001561550-24-000175.md) | [1,863](/filings/0001628280-26-008819.md) | [1,855](/filings/0001561550-25-000123.md) | [1,353](/filings/0001561550-25-000220.md) | [1,321](/filings/0001561550-25-000313.md) | [1,591](/filings/0001628280-26-054458.md) | [1,656](/filings/0001628280-26-032328.md) | [1,875](/filings/0001628280-26-054458.md) |
| Total liabilities | $m | [1,737](/filings/0001561550-23-000055.md) | [1,911](/filings/0001561550-25-000025.md) | [1,939](/filings/0001561550-24-000051.md) | [2,005](/filings/0001561550-24-000112.md) | [2,002](/filings/0001561550-24-000175.md) | [3,071](/filings/0001628280-26-008819.md) | [3,094](/filings/0001561550-25-000123.md) | [2,627](/filings/0001561550-25-000220.md) | [2,613](/filings/0001561550-25-000313.md) | [2,912](/filings/0001628280-26-054458.md) | [2,964](/filings/0001628280-26-032328.md) | [3,181](/filings/0001628280-26-054458.md) |
| Shareholders' equity | $m | [1,806](/filings/0001561550-24-000175.md) | [2,025](/filings/0001628280-26-008819.md) | [2,202](/filings/0001561550-25-000220.md) | [2,407](/filings/0001561550-25-000313.md) | [2,629](/filings/0001561550-25-000313.md) | [2,714](/filings/0001628280-26-054458.md) | [2,917](/filings/0001628280-26-054458.md) | [3,196](/filings/0001628280-26-054458.md) | [3,439](/filings/0001561550-25-000313.md) | [3,732](/filings/0001628280-26-054458.md) | [3,988](/filings/0001628280-26-054458.md) | [4,367](/filings/0001628280-26-054458.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [153 d](/filings/0001561550-24-000175.md) | [220 d](/filings/0001628280-26-008819.md) | [212](/filings/0001561550-25-000123.md) | [164 d](/filings/0001561550-25-000220.md) | [229 d](/filings/0001561550-25-000313.md) | [265 d](/filings/0001628280-26-008819.md) | [272](/filings/0001628280-26-032328.md) | [200 d](/filings/0001628280-26-054458.md) | [251 d](/filings/0001561550-25-000313.md) | [327 d](/filings/0001628280-26-008819.md) | [335](/filings/0001628280-26-032328.md) | [316 d](/filings/0001628280-26-054458.md) |
| Capital expenditure | $m | [6.1 d](/filings/0001561550-24-000175.md) | [10.4 d](/filings/0001628280-26-008819.md) | [14.2](/filings/0001561550-25-000123.md) | [4.4 d](/filings/0001561550-25-000220.md) | [8.4 d](/filings/0001561550-25-000313.md) | [7.8 d](/filings/0001628280-26-008819.md) | [8.7](/filings/0001628280-26-032328.md) | [15.2 d](/filings/0001628280-26-054458.md) | [16.8 d](/filings/0001561550-25-000313.md) | [8.9 d](/filings/0001628280-26-008819.md) | [11.4](/filings/0001628280-26-032328.md) | [9.9 d](/filings/0001628280-26-054458.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [316](/filings/0001561550-23-000055.md) | [319](/filings/0001561550-24-000051.md) | [322](/filings/0001561550-24-000112.md) | [351](/filings/0001561550-24-000175.md) | [356](/filings/0001561550-25-000123.md) | [357](/filings/0001561550-25-000220.md) | [358](/filings/0001561550-25-000313.md) | [363](/filings/0001628280-26-032328.md) | [359](/filings/0001628280-26-054458.md) | [362](/filings/0001561550-25-000313.md) | [365](/filings/0001628280-26-032328.md) | [371](/filings/0001628280-26-054458.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.